Page last updated: 2024-11-13
gt0918
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
proxalutamide: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 60194102 |
| CHEMBL ID | 4594417 |
| SCHEMBL ID | 12494226 |
| MeSH ID | M000608301 |
Synonyms (27)
| Synonym |
|---|
| SCHEMBL12494226 |
| 1398046-21-3 |
| unii-qx6o64gp40 |
| gt-0918 |
| proxalutamide [who-dd] |
| qx6o64gp40 , |
| proxalutamide |
| 4-(4,4-dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile |
| pruxelutamide [inn] |
| pruxelutamide |
| gt0918 |
| kcbjgvdosbkvkp-uhfffaoysa-n |
| HY-103184 |
| CS-0025229 |
| 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile |
| 4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile |
| SB17303 |
| 4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl) benzonitrile |
| Q27287540 |
| AT29744 |
| MS-29600 |
| EX-A5434 |
| CHEMBL4594417 |
| gtpl11992 |
| 4-(4,4-dimethyl-3-{6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl}-5-oxo-2-sulfanylideneimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile |
| DTXSID901102678 |
| AKOS040741823 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events." | ( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021) | 0.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug." | ( Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo. Fan, Y; Gao, C; Ge, Z; Gong, W; He, S; Huang, X; Shan, L; Tong, Y; Wang, Y; Yang, M, 2014) | 0.8 |
| " The results showed that proxalutamide had good oral bioavailability and wide tissue distribution in vivo." | ( Quantitative determination of proxalutamide in rat plasma and tissues using liquid chromatography/tandem mass spectrometry. Gu, S; Peng, Y; Sang, H; Sun, J; Wang, G; Wang, Y; Zhong, Y, 2021) | 0.62 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| ", low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients." | ( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 11 (91.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.01) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (33.33%) | 5.53% |
| Reviews | 2 (16.67%) | 6.00% |
| Case Studies | 2 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||